Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

This phase II trial tests how well gemcitabine, cisplatin and nab-paclitaxel given before surgery (neoadjuvant) works in treating patients with pancreatic cancer that can be removed by surgery (resectable) or that is borderline resectable. The standard treatment for resectable and borderline resectable pancreatic cancer is a combination of surgery and chemotherapy. Neoadjuvant therapy is more feasible and could improve outcomes compared to patients receiving surgery first. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Cisplatin is in a class

Trial Details

NCT ID

NCT06423326

Phase

PHASE2

Sponsor

Emory University

Status

RECRUITING

Cancer Type

Pancreatic Ductal Adenocarcinoma Pancreatic Cancer

Interventions

Biopsy
Biospecimen Collection
Cisplatin
Computed Tomography
Gemcitabine
Magnetic Resonance Imaging

Locations (sample)

Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

Histologically or cytologically confirmed - resectable and borderline resectable pancreatic ductal adenocarcinoma
Resectability will be defined as per National Comprehensive Cancer Network (NCCN) guidelines using cross-sectional imaging (contrast-enhanced compu…
Decisions about resectability status will be made in consensus at multidisciplinary meetings/discussions
Resectable disease will be defined as:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →